Rabbit Recombinant Monoclonal Cannabinoid Receptor I antibody. Suitable for ICC/IF, WB, Flow Cyt (Intra) and reacts with Mouse, Rat, Human samples. Cited in 4 publications.
Images
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img33630.jpg/_jcr_content/renditions/webp-475.webp "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323)")
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img66026.jpg/_jcr_content/renditions/webp-475.webp "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323)")
![Flow Cytometry (Intracellular) - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--flow-cytometry-intracellular-img27101.jpg/_jcr_content/renditions/webp-475.webp "Flow Cytometry (Intracellular) - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323)")
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img7121.jpg/_jcr_content/renditions/webp-475.webp "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323)")
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img58814.jpg/_jcr_content/renditions/webp-475.webp "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (AB259323)")
Publications
Filter by
- Cell death discovery 8:2732022Cannabinoid Receptor-1 suppresses M2 macrophage polarization in colorectal cancer by downregulating EGFR.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYou-Ming Deng,Cheng Zhao,Lei Wu,Zhan Qu,Xin-Yu WangPubMed 35641479
- Molecules (Basel, Switzerland) 27:2022Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs of Rats with Monocrotaline-Induced Pulmonary Hypertension.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAnna Krzyżewska,Marta Baranowska-Kuczko,Anna Jastrząb,Irena Kasacka,Hanna KozłowskaPubMed 35630804
- Cell death discovery 8:1102022New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts.Applications:Unspecified applicationReactive species:Unspecified reactive speciesBo Wang,Dongping Li,Anna Fiselier,Igor Kovalchuk,Olga KovalchukPubMed 35277472
- Oxidative medicine and cellular longevity 2022:10242792022ACEA Attenuates Oxidative Stress by Promoting Mitophagy via CB1R/Nrf1/PINK1 Pathway after Subarachnoid Hemorrhage in Rats.Applications:Unspecified applicationReactive species:Unspecified reactive speciesBinbing Liu,Yang Tian,Yuchen Li,Pei Wu,Yongzhi Zhang,Jiaolin Zheng,Huaizhang ShiPubMed 35251464
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA- Form
- Liquid
- Clonality
- Monoclonal
Immunogen
- The exact immunogen used to generate this antibody is proprietary information.
Reactivity data
Select an application| ICC/IF | IP | WB | IHC-P | IHC-Fr | Flow Cyt (Intra) | |
|---|---|---|---|---|---|---|
| Human | Tested | Not recommended | Tested | Not recommended | Not recommended | Tested |
| Mouse | Tested | Not recommended | Tested | Not recommended | Not recommended | Expected |
| Rat | Tested | Not recommended | Tested | Not recommended | Not recommended | Expected |
ICC/IF
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse | Dilution info 1/100 | Notes - |
Species Rat | Dilution info 1/100 | Notes - |
Species Human | Dilution info 1/100 | Notes - |
IP
Not recommendedNot recommended
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
WB
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species Rat | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
IHC-P
Not recommendedNot recommended
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
IHC-Fr
Not recommendedNot recommended
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Flow Cyt (Intra)
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/500 | Notes - |
ExpectedExpected
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Target data
Function
G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells (PubMed:23955712). Isoform 1. Binds both 2-arachidonoylglycerol (2-AG) and anandamide. Isoform 2. Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 2 in assays measuring GTP binding to membranes. Isoform 3. Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 3 in assays measuring GTP binding to membranes.
Alternative names
CNR, CNR1, Cannabinoid receptor 1, CB-R, CB1, CANN6
Recommended products
Rabbit Recombinant Monoclonal Cannabinoid Receptor I antibody. Suitable for ICC/IF, WB, Flow Cyt (Intra) and reacts with Mouse, Rat, Human samples. Cited in 4 publications.
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA- Form
- Liquid
- Clonality
- Monoclonal
- Immunogen
- The exact immunogen used to generate this antibody is proprietary information.
- Clone number
- EPR23934-20
- Purification technique
- Affinity purification Protein A
- Concentration
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
- Storage information
- Avoid freeze / thaw cycle
Notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
7 product images
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img33630.jpg "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: Lane 1: 3 minutes; Lanes 2-4: 70 seconds.
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323) at 1/1000 dilution
Lane 1: Human brain tissue lysate
Lane 2: Human hippocampus tissue lysate
Lane 3: Mouse brain tissue lysate
Lane 4: Rat brain tissue lysate
SecondaryAll lanes: Western blot - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/1000 dilution
Predicted band size: 53 kDa
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img66026.jpg "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized SH-SY5Y cells labelling Cannabinoid receptor 1 with ab259323 at 1/100 (5.44 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in SH-SY5Y cell line is observed. Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.
![Flow Cytometry (Intracellular) - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--flow-cytometry-intracellular-img27101.jpg "Flow Cytometry (Intracellular) - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Flow Cytometry (Intracellular) - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Intracellular flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized SH-SY5Y (Human neuroblastoma epithelial cell) cells labelling Cannabinoid receptor 1 with ab259323 at 1/500 dilution (0.1ug) (Red) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at 1/2000 dilution was used as the secondary antibody.
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img7121.jpg "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: Lane 1: 67 seconds; Lane 2: 3 minutes.
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323) at 1/1000 dilution
Lane 1: SH-SY5Y (human neuroblastoma epithelial cell) whole cell lysate
Lane 2: NIH/3T3 (mouse embryonic fibroblast) whole cell lysate
SecondaryAll lanes: Western blot - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Predicted band size: 53 kDa
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img58814.jpg "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized mouse primary neuron cells labelling Cannabinoid receptor 1 with ab259323 at 1/500 (1.088 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in mouse primary neuron. Confocal scanning Z step was set as 0.3 μm followed by image processing with maximum Z projection is observed. Anti-MAP2 antibody [HM-2] ab11267 Anti-MAP2 mouse monoclonal antibody was used as counterstain at 1/500 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img12355.jpg "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Blocking and diluting buffer and concentration: 5% NFDM/TBST
The expression profile observed is consistent with what has been described in the literature (PMID: 9655502).
Negative control: mouse liver (PMID: 9655502).
Exposure time: 70 seconds
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323) at 1/1000 dilution
Lane 1: Mouse brain tissue lysate
Lane 2: Mouse liver tissue lysate
SecondaryAll lanes: Western blot - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/1000 dilution
Predicted band size: 53 kDa
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img21249.jpg "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized rat primary neuron cells labelling Cannabinoid receptor 1 with ab259323 at 1/500 (1.088 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in rat primary neuron. Confocal scanning Z step was set as 0.3 μm followed by image processing with maximum Z projection is observed. Anti-MAP2 antibody [HM-2] ab11267 Anti-MAP2 mouse monoclonal antibody was used as counterstain at 1/500 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.
![Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--western-blot-img12355.jpg/_jcr_content/renditions/webp-475.webp "Western blot - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
![Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323), expandable thumbnail](https://content.abcam.com/products/images/cannabinoid-receptor-i-antibody-epr23934-20-ab259323--immunocytochemistry-immunofluorescence-img21249.jpg/_jcr_content/renditions/webp-475.webp "Immunocytochemistry/ Immunofluorescence - Anti-Cannabinoid Receptor I antibody [EPR23934-20] (ab259323)")
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com